Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.47 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726069 | 0.99 | ALDH1A1 (0.47) | ALDH1A1HPGDHSD17B10CNR2S1PR1 | |
| SCHEMBL14569238 | 0.96 | S1PR1 (0.52) | ALDH1A1S1PR1S1PR3S1PR2 | |
| SCHEMBL5726986 | 0.88 | MAPT (0.54) | ALDH1A1 | |
| SCHEMBL5726071 | 0.87 | CNR2 (0.45) | CNR2 | |
| SCHEMBL5724785 | 0.86 | HSD17B3 (0.49) | — | |
| SCHEMBL5725693 | 0.86 | PLA2G4B (0.50) | — | |
| SCHEMBL5725268 | 0.85 | PTGER2 (0.46) | CNR2 | |
| SCHEMBL5730675 | 0.85 | ALDH1A1 (0.52) | ALDH1A1CNR2 | |
| SCHEMBL5046426 | 0.85 | CNR2 (0.61) | ALDH1A1CNR2 | |
| SCHEMBL5726660 | 0.84 | ALDH1A1 (0.63) | ALDH1A1HPGDHSD17B10CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666626-B2 | Antimicrobial articles produced by additive manufacturing | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2023-06-06 | — | — | US | claimed |
| US-20210113651-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (US) | 2021-04-22 | — | — | US | claimed |
| US-10905740-B2 | Antimicrobial articles produced by additive manufacturing | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2021-02-02 | — | — | US | claimed |
| EP-3122393-B1 | SELECTIVE LASER SINTERING PROCESS (SLS) FOR PRODUCING ANTIBIOTIC-ELUTING MEDICAL IMPLANTS | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2020-04-22 | — | — | EP | claimed |
| US-20200061239-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2020-02-27 | — | — | US | claimed |
| US-10406263-B2 | Antimicrobial articles produced by additive manufacturing | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2019-09-10 | — | — | US | claimed |
| EP-2919823-B1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2019-07-03 | — | — | EP | claimed |
| CN-109453433-A | Pass through the antimicrobial article of addition manufacture production | 整形外科创新中心公司 | 2019-03-12 | — | — | CN | claimed |
| US-20170095596-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE (CA) | 2017-04-06 | — | — | US | claimed |
| CN-106456835-A | Antimicrobial articles produced by additive manufacturing | 整形外科创新中心公司 | 2017-02-22 | — | — | CN | claimed |
| EP-1205189-A2 | Combination of a prostaglandin agonist and a HMG-CoA reductase inhibitor for the stimulation of bone growth | Pfizer Products Inc. (US) | 2002-05-15 | — | — | EP | claimed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | claimed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | claimed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| JP-2000507961-A | — | — | 2000-06-27 | — | — | JP | claimed |
| CN-1241176-A | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER (US) | 2000-01-12 | — | — | CN | claimed |
| EP-0951282-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027976-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | ALDH1A1 2216/4885HPGD 20/4885HSD17B10 1860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.